Difference between revisions of "Afuresertib (GSK-2110183)"
Jump to navigation
Jump to search
m |
m |
||
| Line 3: | Line 3: | ||
==Preliminary results== | ==Preliminary results== | ||
| − | # Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C. The novel AKT inhibitor afuresertib shows | + | ===[[Multiple myeloma]]=== |
| − | favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. Epub 2014 Jul 29. [http://www.bloodjournal.org/content/124/14/2190 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/25075128 PubMed] | + | # Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. Epub 2014 Jul 29. [http://www.bloodjournal.org/content/124/14/2190 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/25075128 PubMed] |
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | |||
| + | [[Category:Kinase inhibitors]] | ||
| + | [[Category:AKT1 inhibitors]] | ||
| + | |||
| + | [[Category:Multiple myeloma medications]] | ||
[[Category:Investigational]] | [[Category:Investigational]] | ||
| − | |||
Revision as of 00:01, 14 November 2014
Mechanism of action
Oral AKT1 inhibitor
Preliminary results
Multiple myeloma
- Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. Epub 2014 Jul 29. link to original article PubMed